

Nasdaq: KPRX



## COMPANY OVERVIEW

Kiora Pharmaceuticals (NASDAQ: KPRX) is a clinical-stage biotechnology company developing novel therapies for treating eye diseases. Kiora's lead asset, KIO-301, is a potential first-in-class photoswitch molecule designed to restore lost vision in patients with retinal degenerative diseases like retinitis pigmentosa (RP). This breakthrough approach targets viable retinal neurons, unlike any current vision treatment. Kiora also has additional pipeline assets like KIO-104 for the treatment of non-infectious posterior uveitis, a rare inflammatory eye disease that can lead to vision loss.

With KIO-301 progressing through clinical trials and a seasoned leadership team experienced in commercializing ophthalmic therapies, Kiora is strategically positioned as an emerging player in eye disease drug development. Initial signs of efficacy could enable Kiora to transform treatment paradigms for blinding conditions. Its innovative therapies have blockbuster potential if proven effective in late-stage studies.

## KEY CONSIDERATIONS

- KIO-301 demonstrated improved vision in RP patients in early trials, supporting expansion into additional inherited retinal diseases like Choroideremia and Stargardt's.
- KIO-104 represents a new non-steroidal approach to treating posterior uveitis that can minimize side effects of steroids.
- Kiora is focusing resources on orphan retinal diseases, which will allow efficient development paths leveraging incentives like orphan drug designation.
- Seeking strategic partnerships for non-core assets will provide flexibility to advance promising programs while concentrating internally on lead assets.
- Sharpened clinical focus on high unmet need orphan indications aligns with Kiora's patient-centric mission to restore vision in overlooked diseases.

# KIORA PHARMACEUTICALS: DEVELOPING FIRST-IN-CLASS MEDICINE FOR RARE AND COMMON EYE DISEASES

KIO-301 uses a novel mechanism to restore visual function in patients blinded by degenerative eye diseases

## SEEING HOPE

Kiora develops medicines for blinding eye diseases like retinitis pigmentosa that could restore lost vision.

## FLIPPING THE LIGHT SWITCH

The company's lead therapy KIO-301 makes retina cells light-sensitive again after photoreceptor loss.

## FRESH EYE CARE

Kiora is innovating new therapies for unmet ophthalmic needs like corneal wound healing.

## VISIONARY LEADERSHIP

Seasoned industry veterans guide Kiora's experienced team and promising drug pipeline.

## ADVANCING OCULAR SCIENCE

Novel approaches like KIO-301 offer hope to patients with untreatable retinal conditions.

## TRANSFORMING EYE HEALTH

Strategic partnerships enhance Kiora's capabilities in ophthalmic drug development.

# PIONEERING TREATMENTS FOR SEVERE EYE DISEASES

Kiora Pharmaceuticals is a clinical-stage biotechnology company focused on developing novel therapies for rare, orphan retinal diseases with high unmet needs.

The company is prioritizing the development of its lead asset KIO-301, a first-in-class therapy designed to restore lost vision in inherited retinal degenerations like retinitis pigmentosa (RP), Choroideremia, and Stargardt's Disease. Initial results show KIO-301 improves light detection in RP patients by reactivating viable retinal cells.

Kiora is also progressing with KIO-104 as an innovative treatment for non-infectious uveitis. KIO-104 suppresses inflammation by a different mechanism than steroids to minimize side effects.

By concentrating resources on overlooked orphan ophthalmic conditions, Kiora aims to efficiently transform care for underserved populations. The company is seeking strategic partnerships to advance other promising therapies like KIO-101 for inflammatory eye diseases.

Kiora's patient-centric mission is driven by industry experts with proven experience delivering revolutionary ophthalmic drugs. Their expertise provides confidence in Kiora's ability to successfully restore vision.

Orphan drug incentives will help expedite timelines for KIO-301 and KIO-104. The therapies have blockbuster potential if proven effective in pivotal trials.

With a sharpened focus and clinically validated targets, Kiora is positioned to execute high-value programs transforming treatment paradigms for leading causes of blindness. The company's innovative pipeline aims to dramatically improve the quality of life for patients lacking adequate therapies.

**1,500,000  
MILLION**

People Affected by RP Globally

**\$10.7 Million**

Intangible assets and in-process R&D at year-end 2022

**20+ YEARS**

Patent Protection for KIO-301


**4**

Clinical-Stage Assets In  
Kiora's Pipeline

Nasdaq: **KPRX**



# LEADERSHIP



**BRIAN M. STREM, PHD**  
**PRESIDENT AND CEO**

- Co-founder of Bayon Therapeutics and Okogen
- Former roles in BD and strategy at Sound, Allergan, Shire
- BS in Bioengineering from Cornell, PhD in Biomedical Engineering from UCLA



**ERIC J. DANIELS, MD, MBA**  
**CHIEF DEVELOPMENT OFFICER**

- Nearly 20 years in biotech and medtech
- Former CEO of OccuRx, co-founder of Bayon Therapeutics
- Leadership at Puregraft, Tensys Medical, Cytori Therapeutics
- MD from UCLA, MBA from UCLA, BS in Molecular Biology from Berkeley



**MELISSA TOSCA, CPA**  
**EVP OF FINANCE**

- 22 years in public accounting and biotech finance
- Former Director of Finance at Neomorph and Omniome
- 9 years at Caris Life Sciences in finance leadership roles
- CPA and BS in Accounting from University of Arizona



**STEFAN SPERL, PHD**  
**EVP, CMC, AND OPERATIONS**

- Co-founder and former COO of Panoptes Pharma
- Former global project manager at Nabriva Therapeutics
- Roles in R&D at Biovertis and Wilex
- PhD in Medicinal Chemistry from Max Planck Institute